KPA to demand compensation of Zyprexa tablet

Published: 2003-12-04 06:58:00

Updated: 2003-12-04 06:58:00

Following the price cut of Lilly Korea's Zyprexa (olanzapine) tablet by 14 to 39.9 percent from December 1st in line with its re-designation as the first-line drug in treatment of psychosis, the Korea Pharmaceutical Association delivered its inquiry letter to the president of Lilly Korea, urging ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK